Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial to evaluate the safety and efficacy of induction treatment with lamivudine plus stavudine plus abacavir plus amprenavir/ritonavir followed by supervised treatment interruption in subjects with acute HIV infection or recent seroconversion.

X
Trial Profile

A phase II trial to evaluate the safety and efficacy of induction treatment with lamivudine plus stavudine plus abacavir plus amprenavir/ritonavir followed by supervised treatment interruption in subjects with acute HIV infection or recent seroconversion.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir (Primary) ; Amprenavir (Primary) ; Lamivudine (Primary) ; Ritonavir (Primary) ; Stavudine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Mar 2021 Results assessing neutralizing antibodies responses in the setting of early-ART initiation and their role in shaping post-TI HIV rebound variants presented at the 28th Conference on Retroviruses and Opportunistic Infections
    • 28 Sep 2008 The actual completion date for this trial is Oct 2006 according to ClinicalTrials.gov record.
    • 21 Oct 2005 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top